EMA's September 2026 NAM data pilot lets sponsors share organ-chip and computational data directly with regulators, reshaping ...

Veeva Falcon Safety's E2B(R3) interoperability across all input channels signals the end of dual-entry SAE workflows—here's ...

PMV Pharma's rezatapopt achieves 44% response rate in TP53 Y220C ovarian cancer patients, positioning the drug for potential ...

Girl with Griscelli Syndrome Type II receives first haploidentical transplant at Miami hospital, offering new hope for ...

Elevar presents age-stratified camrelizumab-rivoceranib data from Phase 3 CARES-310 after two FDA rejections, signaling ...

A 38,753-patient cross-trial synthesis in Nature Medicine maps short-term safety of HF combination therapies—signaling how ...

Aprea's APR-1051 early signals are forcing a rapid site expansion—here's what the enrollment acceleration actually costs at ...

Scale AI's CliniCARE-Bench found 34.7% error rates and right-answer-wrong-process failures. The clinical trials field has no ...

Orexo AB settled a 6-year DOJ opioid-marketing investigation for $4M, but the press release names no conduct, no victims, no ...

Mechanical thrombectomy for STEMI with large thrombus burden reduced infarct size by 26% in the NATURE trial, meeting its ...

SRD-002 gene therapy shows sustained HFpEF improvement at 12 months with 80% PCWP normalization from a single intracoronary ...

FDA's July 2026 approval of at-home subcutaneous lecanemab initiation eliminates the 18-month IV requirement, reshaping CNS ...